Key result
Neither ACE inhibitor (HR 0.95; 95% CI 0.82-1.09) nor statin use (HR 1.02; 95% CI 0.87-1.17) was associated with a lower risk of incident mobility limitation over 6.5 years.
Why the study?
Do ACE inhibitors and statins prevent incident mobility limitation in older community-dwelling adults?
Cohort (n=3,055)
Do ACE inhibitors and statins prevent incident mobility limitation in older community-dwelling adults?
Hazard Ratio: 0.95 (95% CI 0.82–1.09)
In older community-dwelling adults, the use of ACE inhibitors or statins does not prevent the development of mobility limitations.
No support for ACE inhibitor or statin initiation to preserve mobility in older adults; leaves open causal effects pending randomized trials.
OBJECTIVES: To evaluate whether the use of angiotensin-converting enzyme (ACE) inhibitors and statins is associated with a lower risk of incident mobility limitation in older community dwelling adults. DESIGN: Longitudinal cohort study. SETTING: Health, Aging and Body Composition (Health ABC) study. PARTICIPANTS: Three thousand fifty-five participants who were well functioning at baseline (no mobility limitations). MEASUREMENTS: Summated standardized daily doses (low, medium, high) and duration of ACE inhibitor and statin use were computed. Mobility limitation (two consecutive self-reports of having any difficulty walking one-quarter of a mile or climbing 10 steps without resting) was assessed every 6 months after baseline. Multivariable Cox proportional hazards analyses were conducted, adjusting for demographics, health status, and health behaviors. RESULTS: At baseline, 15.2% used ACE inhibitors and 12.9% used statins; use of both was greater than 25% by Year 6. Over 6.5 years of follow-up, 49.8% had developed mobility limitation. In separate multivariable models, neither ACE inhibitor (multivariate hazard ratio (HR) = 0.95, 95% confidence interval (CI) = 0.82-1.09) nor statin use (multivariate HR = 1.02, 95% CI = 0.87-1.17) was associated with lower risk of mobility limitation. Similar findings were seen in analyses examining dose-response and duration-response relationships and a sensitivity analysis restricted to those with hypertension. CONCLUSION: ACE inhibitors and statins widely prescribed to treat hypertension and hypercholesterolemia, respectively, do not lower risk of mobility limitation, an important indicator of quality of life.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2011) conducted a cohort in Community-dwelling older adults (n=3,055). Angiotensin-converting enzyme (ACE) inhibitors and statins vs. Non-users was evaluated on Incident mobility limitation (HR 0.95, 95% CI 0.82-1.09). Neither ACE inhibitor (HR 0.95; 95% CI 0.82-1.09) nor statin use (HR 1.02; 95% CI 0.87-1.17) was associated with a lower risk of incident mobility limitation over 6.5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: